Amgen
3Q Revenues: $3.9 billion (+7%)
3Q Earnings: $1.2 billion (earnings were $201 million in 3Q07)
YTD Revenues: $11.3 billion (+3%)
YTD Earnings: $3.2 billion (+39%)
Comments: Sales of Aranesp were up 3% to $845 million. Sales of Epogen increased 5% to $634 million. Combined sales of Neulasta and Neupogen were up 8% to $1.2 billion. Sales of Enbrel were $893 million (+9%). Sales of Sensipar increased 32% to $161 million. R&D expenses were $729 million in the quarter (-6%). Earnings in 3Q07 were negatively impacted by $590 million of acquired in-process R&D related to the acquisitions of Alantos Pharmaceutical Holdings and Ilypsa, Inc., as well as $293 million of restructuring charges.
Magazine
